How Much Does Revlimid Cost?

Published on August 22, 2025 | Prices Last Reviewed for Freshness: January 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer.

Our data shows Revlimid (lenalidomide) remains one of the most expensive oral oncology medicines on the U.S. market, with list prices that pass $18,700–$24,963 for a single 28-day prescription.  Revlimid treats multiple myeloma, mantle-cell lymphoma, and myelodysplastic syndromes. The drug’s patent life, limited competition, and specialty-pharmacy distribution push its price far above typical medicine budgets.

Below, we detail the real-world cost, how insurance and assistance programs change out-of-pocket amounts, and what patients can do to lower the payment burden.

Article Insights

• List price: $18,723–$24,963 per 28-day pack depending on strength.
• Average commercial copay: $32; many pay $0 with copay card.
• Medicare out-of-pocket will cap at $2,000 in 2025.
• Generic lenalidomide ranges $6,800–$10,000 per cycle.
• Assistance foundations fund up to $12,000 yearly.
• Lifetime brand therapy may exceed $1 million without financial aid.

How Much Does Revlimid Cost?

The cost for Revlimid (lenalidomide) is approximately $18,723 to $24,963 per 28-day cycle, depending on the prescribed dosage and treatment regimen.

We gathered the current wholesale acquisition cost (WAC) published by drug databases:

These figures exclude pharmacy mark-ups, dispensing fees, or negotiated rebates. Pricing climbed roughly $1,500 per year between 2018 and 2023, reflecting an annual rise near eight percent. The manufacturer, Bristol Myers Squibb, cites R&D recovery and limited patient volume as drivers, while advocacy groups criticise the trajectory.

For example, the list price is approximately $24,963 per cycle when given as 10 mg once daily for 28 days, and about $18,723 per cycle when given as 25 mg once daily for 21 days of a 28-day cycle, according to Bristol Myers Squibb Pricing Information. These prices represent the wholesale acquisition cost (WAC), which is the price manufacturers charge wholesalers, and most patients pay less depending on insurance coverage and assistance programs.

Other sources, such as Drugs.com, report that the cash price for a supply of 28 capsules of Revlimid 2.5 mg can be around $26,659, with similar pricing for 5 mg and 10 mg capsules. Prices per capsule are roughly $950, making Revlimid one of the most expensive oral cancer drugs on the market. Patient assistance programs and discount cards can help reduce out-of-pocket costs significantly.

Medical News Today highlights that the actual cost to patients varies widely based on insurance plans, copay assistance, and coupons, which can lower the effective price paid. Medicare Part D coverage for Revlimid has become more challenging in 2025, with many plans excluding it from formularies, leading to higher out-of-pocket expenses for seniors.

Investigative reports such as the one from CNN reveal that the price per daily pill of Revlimid can approach nearly $1,000, reflecting the drug’s high cost burden. NPR notes that the manufacturing cost per capsule is only about 25 cents, underscoring the significant markup in retail pricing.

Cost With Commercial Insurance

Data from IQVIA’s 2024 specialty-drug report show that 92 percent of commercially insured patients meet plan deductible thresholds early in the year, dropping their Revlimid copay to an average $32 per month. Employers contract with pharmacy-benefit managers that shift most of the drug price to insurers and reinsurance pools. Bristol Myers Squibb’s Access Support card covers up to $15,000 per calendar year, often turning the remaining cost to $0. Patients must not participate in federal programs and must renew the card annually.

Cost With Medicare and Medicaid 

Medicare Part D places Revlimid on specialty tier five. Beneficiaries first pay plan deductible (often $545) then coinsurance of 25 percent in the standard coverage phase. In 2025 the Inflation Reduction Act caps total Part D out-of-pocket at $2,000, sharply reducing catastrophic spend for Revlimid users. State Medicaid programs classify lenalidomide as medically necessary; most charge $0–$20 per 30-day fill once prior authorization clears. Dual-eligible patients see the Medicaid amount override Part D coinsurance.

Financial Assistance & Manufacturer Support

Bristol Myers Squibb funds three channels:

1. Copay Card: up to $15,000 yearly for privately insured patients earning under 500 percent FPL.
2. Patient Assistance Foundation: free Revlimid for uninsured U.S. residents below 400 percent FPL.
3. Bridge Supply: 60-day courtesy fill when insurance approval is delayed.

Independent foundations such as the PAN Foundation, CancerCare, and HealthWell frequently open Revlimid disease funds. Grants cover $8,000–$12,000 annually and pay the pharmacy directly. Applications need tax returns, insurance documents, and physician statements.

Generic Revlimid (Lenalidomide) Options

Teva, Dr. Reddy’s, and Sun launched approved generics in phased volumes starting 2022. Wholesale quotes show 25 mg generic at $6,800–$8,900 per 21-day pack, roughly 55 percent below brand WAC. Many commercial plans switched to generic tier four, dropping copay to fixed $10–$40. CMS blocks manufacturer coupon use for Medicare, so seniors see minimal difference until Part D negotiations lower brand pricing. Oncology pharmacist Dr. Marina Quintero notes equal bioequivalence, but prescribers must write “substitution permitted” to ensure pharmacy dispensing.

Factors Affecting Out-of-Pocket Costs

• Deductible size: High-deductible health plans front-load spending early in the year.
• Formulary tier: Tier three equals flat $150; tier five triggers percentage coinsurance.
• PBM rebate: Hidden discounts never reach patient bills, skewing public price perception.
• Refill timing: Filling on December 31 may push costs into the next year’s deductible period.
• Coupon eligibility: Federal law bars coupon use with Medicare, VA, or Tricare coverage.

Insurance navigator Elihu Sandino, CPhT advises patients to align refill dates with insurance year-end and to request 90-day supplies when financially favourable.

Cost Comparison With Similar Drugs

• Pomalyst (pomalidomide) – $21,000 per 28-day cycle; reserved for relapsed multiple myeloma.
• Thalomid (thalidomide) – $10,000 per 28-day cycle; higher neuropathy risk limits use.
• Darzalex (daratumumab) – $20,000 per infusion month; often combined with Revlimid.
• Kyprolis (carfilzomib) – $18,000 per two-week dosing; used in doublet or triplet regimens.

Hematologist Dr. Shivani Desai states Revlimid remains first-line because oral dosing, immunomodulatory activity, and survival benefit offset its cost when financial aid succeeds.

Long-Term Cost Considerations

A newly diagnosed patient on front-line Revlimid may stay on therapy for 12 cycles, totalling $225,000–$300,000 at list, before moving to maintenance: 10 mg on days 1–21 of each 28-day month indefinitely. Five years of maintenance at brand WAC approaches $1.2 million. Early enrollment in assistance programs is critical; missing enrollment windows risks retroactive pharmacy bills that exceed household budget.

Drug Pricing Transparency & Regulation

Under the 2022 IRA, CMS begins direct price negotiation for high-spend Part D drugs in 2025, and analysts expect Revlimid to enter round one because it tops Medicare spending tables. Negotiated ceilings may cut Medicare unit prices up to 40 percent by 2026, but private-market impact depends on PBM contract responses. Advocacy director Rebekah Tolman predicts that rebate disclosure rules will force clearer consumer billing, curbing surprise charges at specialty pharmacies.

Answers to Common Questions

How much does Revlimid cost each month without any insurance?

Expect $18,700–$25,000 based on capsule strength and days supplied.

What will I pay with employer insurance?

Most workers pay under $50 per month once deductibles reset, thanks to manufacturer copay support that covers up to $15,000 annually.

Will Medicare help after the new 2025 rules?

Yes. Beginning 2025, total Part D out-of-pocket for all drugs, including Revlimid, cannot exceed $2,000 per year.

Is generic lenalidomide always cheaper?

Commercially insured patients often see lower coinsurance, yet Medicare patients gain little until negotiated prices or new formularies adjust.

Where can I find assistance right now?

Visit Bristol Myers Squibb Access Support, call the PAN Foundation, or ask an oncology social worker to screen you for grants that can cut Revlimid spending to near $0.